Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency

Author(s): Claudia A. Montiel-Equihua, Adrian J. Thrasher, H. Bobby Gaspar.

Journal Name: Current Gene Therapy

Volume 12 , Issue 1 , 2012

Become EABM
Become Reviewer

Abstract:

The severe combined immunodeficiency caused by the absence of adenosine deaminase (SCID-ADA) was the first monogenic disorder for which gene therapy was developed. Over 30 patients have been treated worldwide using the current protocols, and most of them have experienced clinical benefit; importantly, in the absence of any vector-related complications. In this document, we review the progress made so far in the development and establishment of gene therapy as an alternative form of treatment for ADA-SCID patients.

Keywords: Immunodeficiency, Adenosine, Deaminase Deficiency, Adenosine deaminase, severe combined immunodeficiency, gene therapy, hematopoietic stem cell, retrovirus, clinical trial

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 1
Year: 2012
Page: [57 - 65]
Pages: 9
DOI: 10.2174/156652312799789253

Article Metrics

PDF: 67